Cencora, Inc. (NYSE:COR) Receives $399.00 Average PT from Brokerages

Cencora, Inc. (NYSE:COR) has earned an average rating of “Moderate Buy” from the thirteen analysts that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $399.00.

COR has been the subject of several analyst reports. TD Cowen increased their price objective on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Bank of America reduced their target price on Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a report on Monday, January 5th. Mizuho increased their price target on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. UBS Group boosted their price objective on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Finally, Weiss Ratings upgraded Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th.

Cencora Trading Up 0.4%

NYSE COR opened at $360.70 on Wednesday. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. The business has a fifty day simple moving average of $349.41 and a 200 day simple moving average of $330.79. Cencora has a 12 month low of $240.72 and a 12 month high of $377.54. The firm has a market capitalization of $70.17 billion, a P/E ratio of 43.35, a PEG ratio of 1.65 and a beta of 0.68.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.04 by $0.04. The firm had revenue of $85.93 billion during the quarter, compared to analyst estimates of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The business’s revenue was up 5.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.73 EPS. On average, analysts predict that Cencora will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Investors of record on Friday, February 13th will be issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, February 13th. Cencora’s dividend payout ratio (DPR) is 28.85%.

Insiders Place Their Bets

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the transaction, the executive vice president directly owned 23,891 shares in the company, valued at $8,173,111.10. The trade was a 12.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the transaction, the chief executive officer directly owned 66,726 shares of the company’s stock, valued at $23,669,713.98. This represents a 7.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 15,220 shares of company stock valued at $5,282,867. Company insiders own 0.38% of the company’s stock.

Institutional Trading of Cencora

Several hedge funds have recently made changes to their positions in the company. Kovitz Investment Group Partners LLC grew its stake in shares of Cencora by 728.5% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 34,067 shares of the company’s stock worth $11,506,000 after acquiring an additional 29,955 shares during the period. Vancity Investment Management Ltd purchased a new stake in Cencora during the fourth quarter valued at about $248,000. T. Rowe Price Investment Management Inc. boosted its position in Cencora by 160.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock worth $2,262,956,000 after purchasing an additional 4,123,795 shares during the period. Van Diest Capital LLC purchased a new position in shares of Cencora in the fourth quarter worth about $601,000. Finally, Compound Planning Inc. increased its stake in shares of Cencora by 28.1% in the fourth quarter. Compound Planning Inc. now owns 1,505 shares of the company’s stock worth $508,000 after purchasing an additional 330 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.